This dual approach to TB therapy could allow the targeted expansion of functional CD4 T cells with immunotherapy despite the rapid reduction of antigenic bacterial load that occurs with antibiotics, potentially leading to more efficient treatment regimens for TB and enhancing protection against re-infection. Here, CD4 is linked to tuberculosis.